Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (81-90 of 182) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|June 9, 2020
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitorsChristopher Pleyer, Clare Sun, Sanjal Desai, et al.
Cancer Cell|March 5, 2004
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stromaElaine M Hurt, Adrian Wiestner, Andreas Rosenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemiaBruce D Cheson, John C Byrd, Kanti R Rai, et al.
Leukemia|February 26, 2021
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemiaDamian Kovalovsky, Jeong Heon Yoon, Matthew G Cyr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2021
Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with IbrutinibChristian Brieghel, Kathrine Aarup, Mathias H Torp, et al.
Blood|September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S Davids, Jing Deng, Adrian Wiestner, et al.
Leukemia & Lymphoma|March 18, 2021
Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphomaJayalakshmi Balakrishna, Neil Basumallik, Robert Matulonis, et al.
Lancet (London, England)|November 25, 2003
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNAPatrick F Fogarty, Hiroki Yamaguchi, Adrian Wiestner, et al.
Leukemia & Lymphoma|May 10, 2018
Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytesSreenivasulu Gunti, Sarah E M Herman, Raju V S R K Gottumukkala, et al.
Blood|October 18, 2002
Rituximab in the treatment of acquired factor VIII inhibitorsAdrian Wiestner, Hearn J Cho, Adam S Asch, et al.
Pageof 19

Showing results (81-90 of 182) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|June 9, 2020
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitorsChristopher Pleyer, Clare Sun, Sanjal Desai, et al.
Cancer Cell|March 5, 2004
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stromaElaine M Hurt, Adrian Wiestner, Andreas Rosenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemiaBruce D Cheson, John C Byrd, Kanti R Rai, et al.
Leukemia|February 26, 2021
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemiaDamian Kovalovsky, Jeong Heon Yoon, Matthew G Cyr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2021
Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with IbrutinibChristian Brieghel, Kathrine Aarup, Mathias H Torp, et al.
Blood|September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S Davids, Jing Deng, Adrian Wiestner, et al.
Leukemia & Lymphoma|March 18, 2021
Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphomaJayalakshmi Balakrishna, Neil Basumallik, Robert Matulonis, et al.
Lancet (London, England)|November 25, 2003
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNAPatrick F Fogarty, Hiroki Yamaguchi, Adrian Wiestner, et al.
Leukemia & Lymphoma|May 10, 2018
Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytesSreenivasulu Gunti, Sarah E M Herman, Raju V S R K Gottumukkala, et al.
Blood|October 18, 2002
Rituximab in the treatment of acquired factor VIII inhibitorsAdrian Wiestner, Hearn J Cho, Adam S Asch, et al.
Pageof 19